| 
Results for bioinvent. Search took 0.04 seconds.
Genentech Licenses BioInvent's Cardiovascular Drug Candidate
in The Biotech Weblog, on January 15, 2007
... Genentech, Inc . is paying an upfront payment of $15 million to co-develop and commercialize BioInvent ´s proprietary antibody candidate, BI-204 , for the potential treatment of multiple cardiov...